Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

无容量 医学 肝细胞癌 索拉非尼 内科学 丙型肝炎病毒 丙型肝炎 肿瘤科 乙型肝炎 胃肠病学 免疫疗法 免疫学 癌症 病毒
作者
Anthony B. El-Khoueiry,Bruno Sangro,Thomas Yau,Todd S. Crocenzi,Masatoshi Kudo,Chiun Hsu,Tae‐You Kim,Su-Pin Choo,Jörg Trojan,Theodore H. Welling,Tim Meyer,Yoon‐Koo Kang,Winnie Yeo,Akhil Chopra,Jeffrey Anderson,Christine Dela Cruz,Lixin Lang,Jaclyn Neely,Hao Tang,Homa Dastani,Ignacio Melero
出处
期刊:The Lancet [Elsevier]
卷期号:389 (10088): 2492-2502 被引量:3658
标识
DOI:10.1016/s0140-6736(17)31046-2
摘要

Summary

Background

For patients with advanced hepatocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and efficacy of nivolumab, a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor, in patients with advanced hepatocellular carcinoma with or without chronic viral hepatitis.

Methods

We did a phase 1/2, open-label, non-comparative, dose escalation and expansion trial (CheckMate 040) of nivolumab in adults (≥18 years) with histologically confirmed advanced hepatocellular carcinoma with or without hepatitis C or B (HCV or HBV) infection. Previous sorafenib treatment was allowed. A dose-escalation phase was conducted at seven hospitals or academic centres in four countries or territories (USA, Spain, Hong Kong, and Singapore) and a dose-expansion phase was conducted at an additional 39 sites in 11 countries (Canada, UK, Germany, Italy, Japan, South Korea, Taiwan). At screening, eligible patients had Child-Pugh scores of 7 or less (Child-Pugh A or B7) for the dose-escalation phase and 6 or less (Child-Pugh A) for the dose-expansion phase, and an Eastern Cooperative Oncology Group performance status of 1 or less. Patients with HBV infection had to be receiving effective antiviral therapy (viral load <100 IU/mL); antiviral therapy was not required for patients with HCV infection. We excluded patients previously treated with an agent targeting T-cell costimulation or checkpoint pathways. Patients received intravenous nivolumab 0·1–10 mg/kg every 2 weeks in the dose-escalation phase (3+3 design). Nivolumab 3 mg/kg was given every 2 weeks in the dose-expansion phase to patients in four cohorts: sorafenib untreated or intolerant without viral hepatitis, sorafenib progressor without viral hepatitis, HCV infected, and HBV infected. Primary endpoints were safety and tolerability for the escalation phase and objective response rate (Response Evaluation Criteria In Solid Tumors version 1.1) for the expansion phase. This study is registered with ClinicalTrials.gov, number NCT01658878.

Findings

Between Nov 26, 2012, and Aug 8, 2016, 262 eligible patients were treated (48 patients in the dose-escalation phase and 214 in the dose-expansion phase). 202 (77%) of 262 patients have completed treatment and follow-up is ongoing. During dose escalation, nivolumab showed a manageable safety profile, including acceptable tolerability. In this phase, 46 (96%) of 48 patients discontinued treatment, 42 (88%) due to disease progression. Incidence of treatment-related adverse events did not seem to be associated with dose and no maximum tolerated dose was reached. 12 (25%) of 48 patients had grade 3/4 treatment-related adverse events. Three (6%) patients had treatment-related serious adverse events (pemphigoid, adrenal insufficiency, liver disorder). 30 (63%) of 48 patients in the dose-escalation phase died (not determined to be related to nivolumab therapy). Nivolumab 3 mg/kg was chosen for dose expansion. The objective response rate was 20% (95% CI 15–26) in patients treated with nivolumab 3 mg/kg in the dose-expansion phase and 15% (95% CI 6–28) in the dose-escalation phase.

Interpretation

Nivolumab had a manageable safety profile and no new signals were observed in patients with advanced hepatocellular carcinoma. Durable objective responses show the potential of nivolumab for treatment of advanced hepatocellular carcinoma.

Funding

Bristol-Myers Squibb.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
痴情的雁易完成签到,获得积分10
刚刚
上下发布了新的文献求助10
1秒前
3秒前
zheng发布了新的文献求助10
3秒前
kewu完成签到,获得积分20
4秒前
鲜榨白开水完成签到,获得积分10
4秒前
鸡蛋灌饼与掉渣饼完成签到,获得积分10
4秒前
懒大王完成签到,获得积分10
5秒前
ananan应助害羞的裘采纳,获得10
5秒前
6秒前
anyy完成签到 ,获得积分10
6秒前
haoooooooooooooo应助AI采纳,获得10
6秒前
CCC完成签到,获得积分10
6秒前
peansant发布了新的文献求助10
8秒前
胖鲤鱼完成签到,获得积分10
8秒前
冯先生发布了新的文献求助10
9秒前
11秒前
12秒前
沉静青寒完成签到,获得积分10
12秒前
12秒前
在水一方应助锂离子采纳,获得10
13秒前
Aray完成签到 ,获得积分10
13秒前
漂亮的芝发布了新的文献求助10
13秒前
13秒前
15秒前
小可爱发布了新的文献求助10
16秒前
陈上心完成签到,获得积分20
17秒前
小鹿斑比发布了新的文献求助10
17秒前
haochi发布了新的文献求助10
18秒前
19秒前
缺牙巴发布了新的文献求助20
20秒前
踏实的初珍完成签到,获得积分10
21秒前
过儿发布了新的文献求助10
21秒前
21秒前
23秒前
siwuansuan发布了新的文献求助10
23秒前
锂离子发布了新的文献求助10
25秒前
25秒前
小二郎应助甜蜜雅彤采纳,获得10
25秒前
高分求助中
Sustainability in ’Tides Chemistry 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Handbook of the Mammals of the World – Volume 3: Primates 805
Ethnicities: Media, Health, and Coping 800
Gerard de Lairesse : an artist between stage and studio 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3074443
求助须知:如何正确求助?哪些是违规求助? 2727939
关于积分的说明 7501419
捐赠科研通 2376049
什么是DOI,文献DOI怎么找? 1259754
科研通“疑难数据库(出版商)”最低求助积分说明 610754
版权声明 597081